This project consists of financing expenditure of staff specifically recruited for the project, indirect costs associated with such expenditure, depreciation costs of scientific equipment and scientific services. This is a collaborative project between Biopass and Biomarkers, small R & D companies located in Riom (63) and Clermont Auvergne University. This project concerns the “Development of cancer cell lines and three-dimensional (3D) cell lines into bioreactors for preclinical and clinical applications”. Its objective is to: development of tumour and/or 3D cell lines; mass production of these bioreactor lines; and the use of cell lines produced in preclinical (“Cytotoxicity/Drug Effectiveness Screening”) and clinical. At present, the main problem of cell industrialisation is large-scale production capacity. Indeed, 95 % of production is in the form of 2D cultivation and yields are infinitely too low to deal with projects starting industrial production. It is necessary to acquire know-how and mastery in 3D production in order to feed the market and thus open up a new scope in the field of cellular therapy and/or screening of medicinal products.